PWMS News Search Results

Back to NewsWire Home
Back to
  Back to PeopleWithMS NewsWire 

September 2008 Off the Wire . . .



News Article 02raw

Acorda Therapeutics To Present Phase 3 Fampridine-SR Data At World Congress On Treatment And Research In Multiple Sclerosis Meeting

Main Category: Multiple Sclerosis
Article Date: 15 Sep 2008
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that data from its recently-completed Fampridine-SR Phase 3 trial (MS-F204) will be presented during a poster session at the World Congress in Treatment and Research in MS Meeting (ACTRIMS, ECTRIMS and LACTRIMS) on Saturday, September 20, 2008 in Montreal, Canada. The Company previously announced top-line data from MS-F204 on June 2, 2008, and the poster will provide additional data from that clinical trial.

The poster, "Sustained-Release Fampridine Consistently Improves Walking Speed And Leg Strength In Multiple Sclerosis: A Phase 3 Trial," will be presented by Andrew Goodman, M.D., Director of the Multiple Sclerosis Center at the University of Rochester, from 10:00 to 10:30 a.m. ET. Viewing hours will be from 8:30 a.m. to 12:00 p.m. ET in the Viger Foyer outside Room 517.

About Fampridine-SR

Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine (4-aminopyridine or 4-AP). In laboratory studies, fampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged. Fampridine-SR recently completed a second Phase 3 clinical trial to evaluate its safety and efficacy in improving walking ability in people with MS.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda's lead clinical product, Fampridine-SR, recently completed a second Phase 3 clinical trial to evaluate its safety and efficacy in improving walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including delays in obtaining or failure to obtain FDA approval of Fampridine-SR, the risk of unfavorable results from future studies of Fampridine-SR, Acorda Therapeutics' ability to successfully market and sell Fampridine-SR, if approved, and Zanaflex Capsules, competition, failure to protect its intellectual property or to defend against the intellectual property claims of others, the ability to obtain additional financing to support Acorda Therapeutics' operations, and unfavorable results from its preclinical programs. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Acorda Therapeutics

View drug information on Zanaflex.

E-Mail the NewsWire e-mail the NewsWire ! ! ! - Handpainted and Customized Canes
 with any news items you discover 

©copyright 2003